0RK.SG - Exscientia plc
| Previous close | 7.45 |
| Open | 7.50 |
| Bid | 7.25 x N/A |
| Ask | 7.45 x N/A |
| Day's range | 7.25 - 7.50 |
| 52-week range | 3.84 - 13.70 |
| Volume | |
| Avg. volume | 173 |
| Market cap | 931.567M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Motley Fool
Why Shares of Exscientia Soared This Week
Shares of Exscientia (NASDAQ: EXAI) were up 30.3% for the week as of Friday morning, according to data provided by S&P Global Market Intelligence. One reason for this week's share growth was the company's first-quarter earnings report. When chipmaker Nvidia posted strong earnings on the back of AI growth, that helped lift other AI-associated stocks such as Exscientia, which uses AI to help it discover oncology therapies, frequently partnering with larger pharmaceutical companies.
- Motley Fool
Why Artificial Intelligence Stock Exscientia Leaped 6% Higher Today
With a white-hot technology as a foundation for its business, the biotech's better-than-expected first-quarter results brought about a bull stampede.
- Simply Wall St.
Exscientia plc's (NASDAQ:EXAI) largest shareholders are retail investors with 52% ownership, institutions own 27%
Key Insights The considerable ownership by retail investors in Exscientia indicates that they collectively have a...
- Simply Wall St.
Exscientia Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag
Exscientia ( NASDAQ:EXAI ) Full Year 2022 Results Key Financial Results Revenue: UK£27.2m (flat on FY 2021). Net loss...
- Simply Wall St.
Exscientia (NASDAQ:EXAI) shareholders have endured a 55% loss from investing in the stock a year ago
Exscientia plc ( NASDAQ:EXAI ) shareholders should be happy to see the share price up 27% in the last quarter. But...
- Simply Wall St.
Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
- Zacks
Exscientia PLC Sponsored ADR (EXAI) Reports Q3 Loss, Lags Revenue Estimates
Exscientia PLC Sponsored ADR (EXAI) delivered earnings and revenue surprises of -72.73% and 47.93%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Institutions own 27% of Exscientia plc (NASDAQ:EXAI) shares but individual investors control 57% of the company
A look at the shareholders of Exscientia plc ( NASDAQ:EXAI ) can tell us which group is most powerful. With 57% stake...
- Zacks
Oncternal Therapeutics (ONCT) Reports Q3 Loss, Misses Revenue Estimates
Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 12.50% and 11.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Investors in Exscientia (NASDAQ:EXAI) from a year ago are still down 70%, even after 12% gain this past week
Exscientia plc ( NASDAQ:EXAI ) shareholders should be happy to see the share price up 12% in the last week. But that's...
- Simply Wall St.
We're Interested To See How Exscientia (NASDAQ:EXAI) Uses Its Cash Hoard To Grow
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
- Zacks
Wall Street Analysts Think Exscientia PLC Sponsored ADR (EXAI) Could Surge 63%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 62.6% in Exscientia PLC Sponsored ADR (EXAI). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
